# Viracta Therapeutics (VIRX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/VIRX
## Company Profile
- Ticker: VIRX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: Not available
- Market cap: Not available
## Business Overview
Viracta Therapeutics is an oncology company focused on virus-associated cancers and targeted cancer biology. Its platform aims to treat tumors linked to latent viral drivers.
## Why The Stock Is Moving

Current closing-price context is not available for VIRX.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Viracta sits in specialty oncology biotechnology.

## Business Model

The company depends on clinical data, target differentiation, and the ability to build a focused oncology franchise.

## Landscape Position

Viracta is a catalyst-sensitive oncology name whose stock reacts to early clinical and strategic updates.

## Future Catalysts

- Viracta’s catalysts are nanatinostat-based programs in EBV-positive lymphomas and any development update that keeps the antiviral-oncology story alive. The company still needs strong human data.

## Recent News
- 2025-02-05 22:00 EST — [Viracta Therapeutics Announces Wind Down of Operations](https://biopharmsignal.com/news/VIRX/viracta-therapeutics-announces-wind-down-of-operations) — Source: Viracta Therapeutics
- 2024-12-26 21:30 EST — [Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives](https://biopharmsignal.com/news/VIRX/viracta-therapeutics-announces-closure-of-naval-1-clinical-trial-and-exploration-of-strategic-alternatives) — Source: Viracta Therapeutics
- 2024-11-13 12:00 EST — [Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update](https://biopharmsignal.com/news/VIRX/viracta-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update) — Source: Viracta Therapeutics
- 2024-11-06 20:19 EST — [Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma](https://biopharmsignal.com/news/VIRX/viracta-therapeutics-announces-reprioritization-of-resources-to-enhance-focus-on-nana-val-development-program-in-patients-with-relapsed-or-refractory-ebv-positive-peripheral-t-cell-lymphoma) — Source: Viracta Therapeutics
- 2024-09-05 15:32 EST — [Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference](https://biopharmsignal.com/news/VIRX/viracta-therapeutics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference) — Source: Viracta Therapeutics